The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor

ConditionFibromyalgia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorKanuni Sultan Suleyman Training and Research Hospital

About this trial

Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified.

Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Female participants aged between 18 and 50 years

Disqualifiers

None

Trial population

Presence of any systemic disease (hematologic, endocrine, rheumatologic, renal, cardiovascular, gastrointestinal, or respiratory) Active infection History of malignancy Major surgery or trauma within the last 1 year Any treatment for fibromyalgia within the last 3 months Pregnancy or breastfeeding Smoking Vitamin D deficiency

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

  • No Intervention (Observational Study)

    Other intervention

    This is an observational study with no therapeutic or diagnostic intervention. Participants will undergo a single-time-point clinical assessment and venous blood sampling for biomarker measurement only.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Fibromyalgia Group1 intervention
Group B: Healthy Control Group1 intervention

Trial outcomes

Primary outcomes

1

Association between serum S100B and serum BDNF

Serum S100B and serum BDNF concentrations will be measured from venous blood samples and the strength of association between the two biomarkers will be analyzed

Time frame
Baseline

Secondary outcomes

1

Correlation of serum S100B and BDNF with Central Sensitization Inventory (CSI)

Serum S100B and BDNF levels will be correlated with CSI total score to evaluate biomarker association with central sensitization severity.

Time frame
Baseline
2

Correlation of serum S100B and BDNF with Pittsburgh Sleep Quality Index (PSQI)

Serum S100B and BDNF levels will be correlated with PSQI total score to evaluate association with sleep quality.

Time frame
Baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.